Leena Gandhi

Publications

• Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM.Phase I study of Navi
  21282543
• Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J
  20979469
• Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR.Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.Cancer Epidemiol Biomarkers Prev. 2
  20447926
• Gandhi L,McNamara KL,Li D,Borgman CL,McDermott U,Brandstetter KA,Padera RF,Chirieac LR,Settleman JE,Wong KK.Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.Cancer Prev Res (Phila Pa). 2009 Apr;2(4):330-7
  19336729
• Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA.PF00299804, an irreversible pan-ERBB inhibitor, is
  18089823
• Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, Johnson BE, Lynch TJ.A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lu
  17285598
• Gandhi L, Johnson BE.Paraneoplastic syndromes associated with small cell lung cancer.J Natl Compr Canc Netw. 2006 Jul;4(6):631-8. Review.
  16813730